Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tamar Tadmor

Showing results (111-120 of 149) with videos related to

Pageof 15
Sort By:
European Journal of Haematology|October 22, 2020
Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature reviewTamir Shragai, Moshe Gatt, Noa Lavie, et al.
Leukemia Research|June 2, 2019
Primary peg-filgrastim prophylaxis versus filgrastim given "on demand" for neutropenia during therapy with cladribine for hairy cell leukemiaTamar Tadmor, Ilana Levy, Yair Herishanu, et al.
Leukemia Research|March 5, 2018
Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcomeChezi Ganzel, Ory Rouvio, Irit Avivi, et al.
Haematologica|July 29, 2021
Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemiaOhad Benjamini, Lior Rokach, Gilad Itchaki, et al.
Palliative Medicine|March 25, 2021
Willingness and concerns of transfusion-dependent hematological patients toward the option of home transfusion therapyLiza Barki-Harrington, Orna Baron-Epel, Adir Shaulov, et al.
Leukemia & Lymphoma|September 8, 2022
Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study GroupChezi Ganzel, Svetlana Trestman, Shai Levi, et al.
Leukemia & Lymphoma|October 10, 2025
Expert consensus opinion on the management of hairy cell leukemia in elderly patientsTamar Tadmor, Judit Demeter, Andrei Fagarasanu, et al.
British Journal of Haematology|October 7, 2022
Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective studyTamir Shragai, Hila Magen, Noa Lavi, et al.
Blood Advances|December 5, 2024
Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort studyOfir Wolach, Itai Levi, Boaz Nachmias, et al.
British Journal of Haematology|June 8, 2017
Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patientsEldad J Dann, Osnat Bairey, Rachel Bar-Shalom, et al.
Pageof 15

Showing results (111-120 of 149) with videos related to

Sort By:
Pageof 15
European Journal of Haematology|October 22, 2020
Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature reviewTamir Shragai, Moshe Gatt, Noa Lavie, et al.
Leukemia Research|June 2, 2019
Primary peg-filgrastim prophylaxis versus filgrastim given "on demand" for neutropenia during therapy with cladribine for hairy cell leukemiaTamar Tadmor, Ilana Levy, Yair Herishanu, et al.
Leukemia Research|March 5, 2018
Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcomeChezi Ganzel, Ory Rouvio, Irit Avivi, et al.
Haematologica|July 29, 2021
Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemiaOhad Benjamini, Lior Rokach, Gilad Itchaki, et al.
Palliative Medicine|March 25, 2021
Willingness and concerns of transfusion-dependent hematological patients toward the option of home transfusion therapyLiza Barki-Harrington, Orna Baron-Epel, Adir Shaulov, et al.
Leukemia & Lymphoma|September 8, 2022
Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study GroupChezi Ganzel, Svetlana Trestman, Shai Levi, et al.
Leukemia & Lymphoma|October 10, 2025
Expert consensus opinion on the management of hairy cell leukemia in elderly patientsTamar Tadmor, Judit Demeter, Andrei Fagarasanu, et al.
British Journal of Haematology|October 7, 2022
Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective studyTamir Shragai, Hila Magen, Noa Lavi, et al.
Blood Advances|December 5, 2024
Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort studyOfir Wolach, Itai Levi, Boaz Nachmias, et al.
British Journal of Haematology|June 8, 2017
Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patientsEldad J Dann, Osnat Bairey, Rachel Bar-Shalom, et al.
Pageof 15